株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

子宮頸癌の分析・予測

Cervical Cancer Disease Coverage Forecast and Market Analysis to 2023

発行 Datamonitor Healthcare 商品コード 527415
出版日 ページ情報 英文 69 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.38円で換算しております。
Back to Top
子宮頸癌の分析・予測 Cervical Cancer Disease Coverage Forecast and Market Analysis to 2023
出版日: 2017年06月12日 ページ情報: 英文 69 Pages
概要

当レポートでは、世界の子宮頸癌の罹患状況を調査し、主要国・FIGOステージ別の子宮頸癌発症数の推移と予測、国による子宮頸部スクリーニングプログラム・予防接種プログラムなどをまとめています。

目次

  • エグゼクティブサマリー
  • 疾患の背景
  • 情報源・調査手法
  • 予測
  • 疫学者の考察
  • 強み・制約

図表

  • 米国・日本・EU5カ国における子宮頸癌発症数の推移と予測:国別
  • 子宮頸癌発症数実績:FIGOステージ・国別
  • 子宮頸部スクリーニングプログラム・スクリーニングカバレージ:国別
  • HPV予防接種プログラム:国別、など
目次
Product Code: DMKC5632

Cervical cancer is a major gynecological cancer which involves uncontrolled cell division and tissue invasiveness of the female uterine cervix. Incidence rates are highest in sub-Saharan Africa, Latin America and the Caribbean, and Oceania/Australasia, and lowest in Western Asia, Australia/New Zealand, and Northern America. Human papillomavirus (HPV) is a major cause of the main types of cervical cancer (the two main histological subtypes being squamous cell cancer and adenocarcinoma), and is believed to be responsible for around 95% of cervical cancers.

TABLE OF CONTENTS

EPIDEMIOLOGY: CERVICAL CANCER

  • Executive Summary
  • Disease Background
  • Sources and Methodology
  • Forecast
  • Epidemiologist Insight
  • Strengths and Limitations

APPENDIX

  • Appendix: Epidemiology: Cervical Cancer

LIST OF FIGURES

  • Figure 1: Trends in incident cases of cervical cancer in the US, Japan, and five major EU markets, by country, 2016-36
  • Figure 2: Absolute change in incident cases of cervical cancer in the US, Japan, and five major EU markets, by country, 2016-36
  • Figure 3: Incident cervical cancer cases, by FIGO stage and country, 2016

LIST OF TABLES

  • Table 1: Cervical cancer ICD-O-3 topography codes
  • Table 2: Cervical cancer staging, according to TNM and FIGO staging
  • Table 3: Cancer registry databases used as a source of cervical cancer incidence data, by country
  • Table 4: Forecasting methodology for cervical cancer incidence, by country and age group
  • Table 5: Data sources used to segment incident cervical cancer cases by FIGO stage, by country
  • Table 6: Data sources used to segment incident cervical cancer cases by histological subtype
  • Table 7: Incident cases of cervical cancer in the US, Japan, and five major EU markets, by country, 2016-36
  • Table 8: Age-specific incident cases of cervical cancer in the US, Japan, and five major EU markets, by country, 2016
  • Table 9: Proportion and number of incident cases of cervical cancer in the US, Japan, and five major EU markets, by FIGO stage and country, 2016
  • Table 10: Proportion and number of incident cases of cervical cancer in the US, Japan, and five major EU markets, by histological subtype and country, 2016
  • Table 11: Cervical screening programs and screening coverage, by country
  • Table 12: National HPV immunization programs in girls, by country
  • Table 13: Validation of cervical cancer forecast estimates against benchmark estimates, by country
Back to Top